前沿速览057期| CAR-T治B淋 前沿览新知
01
CAR-T vs. 双特异性抗体治疗复发/难治性惰性B细胞非霍奇金淋巴瘤的临床结局对比: 一项荟萃分析
Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas
第一作者：Zhang MY
J Transl Med (IF=7.5). 2025 Dec 27.
全文网址：https://link.springer.com/article/10.1186/s12967-025-07571-3
02
早期CAR-T细胞治疗复发/难治性大B细胞淋巴瘤可降低血液毒性负荷
Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden
第一作者：Zeremski V
Blood Adv (IF=7.1). 2025 Dec 18:bloodadvances.2025018353.
全文网址：https://ashpublications.org/bloodadvances/article-lookup/doi/10.1182/bloodadvances.2025018353
03
CAR-T细胞治疗患者的重症监护经验：六年间ICU收治、管理与预后趋势
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU
第一作者：Rajendram P
Crit Care Med (IF=6.0). 2025 Dec 30.
全文网址：https://journals.lww.com/ccmjournal/abstract/9900/six_year_trends_in_icu_admission,_management,_and.709.aspx
04
单细胞与bulk转录组学揭示CD8⁺ T细胞基因标签对弥漫大B细胞淋巴瘤预后的预测价值
Single-cell and bulk transcriptomics reveal a CD8(+) T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma
第一作者：Liu H
Front Immunol (IF=5.9). 2025 Dec 12;16:1685541.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12740938/
05
CAR-T 细胞疗法能否真正惠及所有患者？商业性CAR-T细胞疗法可及性的障碍、促进因素与干预措施
CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access
第一作者：Kaparis S
Blood Rev (IF=5.7). 2025 Dec 16:101358.
全文网址：https://www.sciencedirect.com/science/article/pii/S0268960X25001031?via%3Dihub
06
迈向个体化清淋：接受CAR-T细胞治疗患者中氟达拉滨的群体药代动力学模型
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy
第一作者：Varela-González-Aller J
Pharmaceutics (IF=5.5). 2025 Dec 10;17(12):1592.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12736365/
07
复发/难治性套细胞淋巴瘤中CAR-T细胞治疗的真实世界适用性、应用情况与障碍
Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma
第一作者：Puckrin R
Bone Marrow Transplant (IF=5.2). 2025 Dec 26.
全文网址：https://www.nature.com/articles/s41409-025-02786-w
08
Pomalidomide可增强CAR-T细胞的疗效并重塑淋巴恶性肿瘤的免疫微环境
Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
第一作者：Zhou Y
Cancer Immunol Immunother (IF=5.1). 2025 Dec 18;75(1):9.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12715080/
09
Tisagenlecleucel治疗复发/难治性弥漫大B细胞淋巴瘤的韩国真实世界经验
Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea
第一作者：Kim DH
Ther Adv Hematol (IF=3.1). 2025 Dec 22;16:20406207251406461.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12722673/
10
在复发/难治性滤泡性淋巴瘤治疗中，Axicabtagene ciloleucel 相较于既往可用的治疗方案展现出更优的长期疗效：ZUMA-5研究 vs. SCHOLAR-5研究五年随访数据对比分析
Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5
第一作者：Gribben JG
Leuk Lymphoma (IF=2.2). 2025 Dec 30:1-5.
全文网址：https://www.tandfonline.com/doi/10.1080/10428194.2025.2604306?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2026.1-5 valid until 2028.1
供稿与审核：临床开发与医学部